American Cancer Society: Cancer Facts and Figures 2024. Available online Exit Disclaimer. 2024. Accessed January 17, 2024.

Addeo A, Banna GL, Friedlaender A. Tarlatamab: a potential new option for recurrent small cell lung cancer. Transl Lung Cancer Res. 2023;12:1628–30. https://doi.org/10.21037/tlcr-23-215.

Article  PubMed Central  Google Scholar 

PDQ® Adult Treatment Editorial Board. PDQ Small Cell Lung Cancer Treatment. Bethesda, MD: National Cancer Institute. 2024. https://www.cancer.gov/types/lung/hp/small-cell-lung-treatment-pdq. Accessed 20 June 2024.

Rudin CM, Reck M, Johnson ML, Blackhall F, Hann CL, Yang JC, Bailis JM, Bebb G, Goldrick A, Umejiego J, Paz-Ares L. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J Hematol Oncol. 2023;16:66. https://doi.org/10.1186/s13045-023-01464-y.

Article  PubMed Central  Google Scholar 

Fry WA, Menck HR, Winchester DP. The national cancer data base report on lung cancer. Cancer. 1996;77:1947–55.

Article  Google Scholar 

Dingemans AM, Früh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, Lantuejoul S, Peters S, Reguart N, Rudin CM, De Ruysscher D. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:839–53. https://doi.org/10.1016/j.annonc.2021.03.207.

Article  Google Scholar 

Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, Majem M, Nackaerts K, Syrigos K, Hansen K, Schuette W. Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study. J Thorac Oncol. 2021;16:1547–58. https://doi.org/10.1016/j.jtho.2021.02.009.

Article  Google Scholar 

Serani S. FDA Grants Approval to Tarlatamab in Small Cell Lung Cancer. 2024. https://www.targetedonc.com/view/fda-grants-approval-to-tarlatamab-in-small-cell-lung-cancer. Accessed 16 May 2024.

FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer. News release. US FDA. May 16, 2024. https://tinyurl.com/bddwjpk2. Accessed 16 May 2024.

FDA grants priority review to Amgen’s tarlatamab application for advanced small cell lung cancer. News release. Amgen. December 13, 2023. Accessed April 19, 2024.

Avanza T. FDA approves Imdelltra™ (Tarlatamab-Dlle), the first and only T-cell engager therapy for the treatment of extensive-stage small cell lung cancer. 2024. Accessed May 16, 2024.

Richards R. Investing News Network Your trusted source for investing success. 2024. Accessed 20 Apr 2024.

Owen DH, Giffin MJ, Bailis JM, Smit MA, Carbone DP, He K. DLL3: an emerging target in small cell lung cancer. J Hematol Oncol. 2019;12:1–8. https://doi.org/10.1186/s13045-019-0745-2.

Article  Google Scholar 

Tang D, Kang R. Tarlatamab: the promising immunotherapy on its way from the lab to the clinic. Transl Lung Cancer Res. 2023;12:1355. https://doi.org/10.21037/tlcr-23-115.

Article  PubMed Central  Google Scholar 

Khosla AA, Jatwani K, Singh R, Reddy A, Jaiyesimi I, Desai A. Bispecific antibodies in lung cancer: a state-of-the-art review. Pharmaceuticals. 2023;16:1461. https://doi.org/10.3390/ph16101461.

Article  PubMed Central  Google Scholar 

Oronsky B, Abrouk N, Caroen S, Lybeck M, Guo X, Wang X, Yu Z, Reid T. A 2022 update on extensive-stage small-cell lung cancer (SCLC). J Cancer. 2022;13:2945. https://doi.org/10.7150/jca.75622.

Article  PubMed Central  Google Scholar 

Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14:549–61. https://doi.org/10.1038/nrclinonc.2017.71.

Article  PubMed Central  Google Scholar 

Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389:2063–75. https://doi.org/10.1056/NEJMoa2307980.

Article  Google Scholar 

Cooke K, Estrada J, Zhan J, Werner J, Caenepeel S, Giffin M, Bailis JM, Coxon A, Hughes PE, Canon J. Antitumor activity of AMG757, a half-life extended (HLE) bispecific T-cell engager (BiTE®) immune therapy targeting DLL3, in human PDX and orthotopic mouse models of small cell lung cancer (SCLC). Cancer Res. 2020;80(16_Supplement):4558–4558. https://doi.org/10.1158/1538-7445.AM2020-4558.

Article  Google Scholar 

Giffin MJ, Cooke K, Lobenhofer EK, Estrada J, Zhan J, Deegen P, Thomas M, Murawsky CM, Werner J, Liu S, Lee F. AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27:1526–37. https://doi.org/10.1158/1078-0432.CCR-20-2845.

Article  Google Scholar 

Cooke K, Estrada J, Zhan J, Werner J, Bailis J, Hughes P, Shetty A, Canon J, Smit M. P15. 01 AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE® immune therapy) targeting DLL3, for the treatment of small cell lung cancer. J Thor Oncol. 2021;16:S343–4. https://doi.org/10.1016/j.jtho.2021.01.538.

Article  Google Scholar 

Lobenhofer E, Werner J, Giffin M, Engwall M, Davies R, Homann O, Lafleur M, Moffat G. P1. 12-18 Nonclinical safety assessment of AMG 757, a DLL3 bispecific T cell engager, in the Cynomolgus Monkey. J Thor Oncol. 2019;14:S541. https://doi.org/10.1016/j.jtho.2019.08.1131.

Article  Google Scholar 

Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Tarlatamab, a First-in-Class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: An open-label, phase I study. J Clin Oncol. 2023;41:2893–903. https://doi.org/10.1200/JCO.22.02823.

Article  PubMed Central  Google Scholar 

Ramalingam SS, Ahn MJ, Akamatsu H, Blackhall FH, Borghaei H, Hummel HD, Johnson ML, Reck M, Zhang Y, Jandial D, Cheng S. Phase 2 study of tarlatamab, a DLL3-targeting, half-life–extended, bispecific T-cell engager (HLE BiTE) immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC). J Clin Oncol. 2022;40. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS8603

Gadgeel SM, Al-Mondhiry J, Ahn MJ, Kim SW, Paz-Ares L, Prenen H, Boyer M, Alvarez JB, Solomon B, Huang S, Minocha M. 1549TiP DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC). Ann Oncol. 2022;33:S1255. https://doi.org/10.1016/j.annonc.2022.07.1643.

Article  Google Scholar 

Paz-Ares LG, Felip E, Ahn MJ, Blackhall FH, Borghaei H, Cho BC, Johnson ML, Ramalingam SS, Reck M, Zhang A, Ju CH. Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304). 2023. https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS8611

Su PL, Chakravarthy K, Furuya N, Brownstein J, Yu J, Long M, Carbone D, Li Z, He K. DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy. Mol Cancer. 2024;23:97. https://doi.org/10.1186/s12943-024-02012-z.

Article  PubMed Central  Google Scholar 

Moreau P, Garfall AL, van de Donk NW, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495–505. https://doi.org/10.1056/NEJMoa2203478.

Article  PubMed Central  Google Scholar 

Tendler S, Rudin CM. Tarlatamab: new star on the horizon for small-cell lung cancer? J Clin Oncol. 2023;41:2877–80.

Article  PubMed Central  Google Scholar 

Simão DC, Zarrabi KK, Mendes JL, Luz R, Garcia JA, Kelly WK, Barata PC. Bispecific T-cell engagers therapies in solid tumors: Focusing on prostate cancer. Cancers. 2023;15:1412. https://doi.org/10.3390/cancers15051412.

Article  PubMed Central  Google Scholar 

Cooke K, Estrada J, Zhan J, Werner J, Lee F, Shetty A, Smit MA, Salvati M, Bailis J. 627 The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer. 2020. https://doi.org/10.1136/jitc-2020-SITC2020.0627

Dingemans AM, Ahn MJ, Blackhall FH, Reck M, Hummel HD, Ramalingam SS, Johnson ML, Akamatsu H, Wolf J, Sands J, Owonikoko TK. DeLLphi-301: Tarlatamab phase 2 trial in small cell lung cancer (SCLC)—Efficacy and safety analyzed by presence of brain metastasis. 2024. https://doi.org/10.1200/JCO.2024.42.16_suppl.8015

Trillo Aliaga P, Del Signore E, Fuorivia V, Spitaleri G, Asnaghi R, Attili I, Corvaja C, Carnevale Schianca A, Passaro A, de Marinis F. The evolving scenario of ES-SCLC management: From biology to new cancer therapeutics. Genes. 2024;15:701. https://doi.org/10.3390/genes15060701.

Article  PubMed Central  Google Scholar 

Study Comparing Tarlatamab and Durvalumab versus Durvalumab alone in first-line extensive-stage small-cell lung cancer (ES-SCLC) following Platinum, Etoposide and Durvalumab (DeLLphi-305). https://classic.clinicaltrials.gov/ct2/show/NCT06211036. Accessed 29 Jun 2024.

Study Evaluating Tarlatamab After Chemoradiotherapy in limited-stage small-cell lung cancer (LS-SCLC) (DeLLphi-306). https://classic.clinicaltrials.gov/ct2/show/NCT06117774. Accessed 1 Jul 2024.

A Study of AMG 757 in participants with neuroendocrine prostate cancer (DeLLpro-300). https://classic.clinicaltrials.gov/ct2/show/NCT04702737, Accessed 23 June 2024.

Stumpo S, Formelli MG, Persano I, Parlagreco E, Lauricella E, Rodriquenz MG, Guerrera LP, Zurlo IV, Campana D, Brizzi MP, Cives M, La Salvia A, Lamberti G. Extrapulmonary neuroendocrine carcinomas: current management and future perspectives. J Clin Med. 2023;12:7715. https://doi.org/10.3390/jcm12247715.

Article  PubMed Central  Google Scholar 

Aggarwal RR, Rottey S, Aparicio A, Greil R, Reimers MA, Sandhu SK, Zhang Y, Salvati M, Hashemi Sadraei N (2022) Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC). https://doi.org/10.1200/JCO.2022.40.6_suppl.TPS19.

Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B, von Bergwelt-Baildon MS. Cytokine release syndrome. J Immunother. Cancer. 2018;6:1–4. https://doi.org/10.1186/s40425-018-0343-9.

Article  Google Scholar 

Li J, Piskol R, Ybarra R, Chen YJ, Li J, Slaga D, Hristopoulos M, Clark R, Modrusan Z, Totpal K, Junttila MR, Junttila TT. CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity. Sci Transl Med. 2019;11:861. https://doi.org/10.1126/scitranslmed.aax8861.

Article  Google Scholar 

Tarlatamab (AMG 757) expanded access protocol for advanced small cell lung cancer. https://classic.clinicaltrials.gov/ct2/show/NCT06064500. Accessed 20 May 2024.